NIA Impact Advisors’s CRISPR Therapeutics CRSP Stock Holding History

NIA Impact Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,620	Closed	-$254K	–	54
2023 Q1	$254K	Sell	5,620 -2,598	-32%	-$126K	0.14%	48
2022 Q4	$334K	Sell	8,218 -4,660	-36%	-$247K	0.19%	49
2022 Q3	$842K	Sell	12,878 -32,158	-71%	-$2.33M	0.52%	49
2022 Q2	$2.74M	Sell	45,036 -35,046	-44%	-$2.06M	1.64%	22
2022 Q1	$5.03M	Buy	80,082 +17,473	+28%	+$1.1M	2.44%	16
2021 Q4	$3.88M	Buy	62,609 +2,110	+3%	+$184K	2.06%	18
2021 Q3	$6.77M	Buy	60,499 +20,608	+52%	+$2.59M	2.89%	14
2021 Q2	$6.46M	Buy	39,891 +1,999	+5%	+$243K	3.15%	12
2021 Q1	$4.62M	Buy	37,892 +4,412	+13%	+$666K	2.5%	19
2020 Q4	$6.51M	Buy	+33,480	New	+$3.96M	3.39%	7

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIA Impact Advisors's CRSP Position: Q2 2023 in Review

NIA Impact Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 5,620 shares — an estimated $254K sold.

NIA Impact Advisors first reported a position in CRSP in Q4 2020 and held it in 10 quarters. The position peaked at $6.77M in Q3 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

NIA Impact Advisors reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
NIA Impact Advisors sold 5,620 CRISPR Therapeutics shares in Q2 2023, an estimated $254K.
NIA Impact Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 10 quarters.
NIA Impact Advisors's CRISPR Therapeutics position peaked at $6.77M in Q3 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on NIA Impact Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.